RSV vaccine products

Summary of RSV vaccine products in late-stage development

This infographic provides a summary of respiratory syncytial virus (RSV) vaccine products in late-stage clinical development. It also shows the timeline of the clinical testing of these RSV products and their respective target populations, as of July 1, 2019.

Janssen is developing a vaccine program for infants and older adults. For infants, they are in Phase 2 clinical trials with a vectored antigen from Adenovirus 26 (Ad26). The Ad26 vectored antigen is also in Phase 2 clinical trials in older adults, potentially with a subunit protein.

AstraZeneca/Sanofi Pasteur is developing nirsevimab (MEDI8897) a monoclonal antibody targeted for infants. It is currently in Phase 2 clinical trials.

GSK is developing a vaccine program for pregnant women, infants and older adults. For pregnant women and older adults, they are developing a subunit protein vaccine. For infants, they are developing a Chimpanzee Adenovirus 155 (ChAd155)-vectored antigen. All the programs are in Phase 2 clinical trials.

Novavax is developing a particle-based vaccine for pregnant women and older adults. These programs are currently in Phase 3 clinical trials.

Bavarian Nordic is developing a modified vaccinia Ankara (MVA)-vectored vaccine targeted for older adults, currently in Phase 2 clinical trials.